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Glioblastoma (GBM) is a malignant brain tumor that kills most patients within 2 years. In this issue of Cancer
Cell, Noushmehr et al., through The Cancer Genome Atlas (TCGA) project, provide one of the first integrated
views of the GBM methylome, adding to our increasingly comprehensive understanding of this disease.Epigenetic events are heritable changes
in gene expression that are not accompa-
nied by changes in DNA sequence.
This epigenetic information—collectively
termed the epigenome—helps to regulate
the integrity and expression of genes in
normal eukaryotic cells (Suzuki and Bird,
2008). In addition to its role in normal cells,
there is increasing evidence that aberrant
epigenetic events contribute to disease
states, most notably cancer (Jones and
Baylin, 2007). Several processes appear
to mediate epigenetic control, including
DNA methylation, histone modification,
and nucleosome remodeling. Among
these, hypermethylation of promoter
regions has emerged as one of the best
described epigenetic changes in tumors.
These promoter regions contain cytosine
phosphate guanine (CpG) islands, short
regions of 0.5–4 kilobases rich in CpG
content, that are generally unmethylated
in normal cells (Jones and Baylin, 2007).
Understanding the aberrant epigenetic
changes in cancer has formulated around
two key hypotheses: Promoter methyla-
tion can silence tumor suppressor genes,
and aberrant epigenetic events occur
across the genome, resulting in specific
patterns of gene inactivation that contrib-
utes to the cancer state.
The appreciation that epigenetic events
are a genome-wide phenomenon has led
to the development of technologies that
detect global patterns of methylation. In
this issue of Cancer Cell, Noushmehr
and colleagues present a comprehensive
study of the methylome of human glio-
blastoma (GBM), the most common and
malignant primary brain tumor (Noush-
mehr et al., 2010). Although DNA methyl-
ation alterations in GBM have been widely
reported, the work by Noushmehr and
colleagues is particularly significant
because it focuses on the large cohort ofGBM collected and studied through The
Cancer Genome Atlas (TCGA) network
(TCGA, 2008). The TCGA aims to charac-
terize cancer genomes to identify means
of improving cancer prevention, detection,
and therapy. Previous TCGA efforts have
identified subgroups of GBM by profiling
patterns of mRNA expression, single-
nucleotide polymorphism (SNP) copy-
number change, and mutation across
>200 tumors (Figure 1). These subgroups
are defined predominantly by patterns of
gene expression and include proneural,
neural, classical, and mesenchymal types
(Phillips et al., 2006; TCGA, 2008). Muta-
tions and altered expression of EGFR,
NF1, and PDGFRA/IDH1 have further
defined the classical, mesenchymal, and
proneural subgroups, respectively (Ver-
haak et al., 2010). The work reported by
Noushmehr and colleagues casts an addi-
tional layer of complexity across these
emerging GBM subgroups, thereby
providing exemplary evidence of the value
of the TCGA (Figure 1).
Using the Illumina GoldenGate and
Infinium platforms, Noushmehr and
colleagues measured global patterns of
methylation across a discovery set of
272 TCGA GBM samples. Similar to prior
TCGA genomic studies, methylome
profiling divided the GBM cohort into sub-
groups. Of the three methylome sub-
groups identified, one included tumors
with a very robust pattern of DNA methyl-
ation, reminiscent of the CpG island meth-
ylator phenotype (CIMP) observed in
colorectal cancer (Toyota et al., 1999).
Like the colorectal-CIMP, the glioma
(G)-CIMP was characterized by cancer-
specific CpG island hypermethylation of
a subset of genes.
Because the GBM subgroups have
been best described by patterns of
mRNA expression, the authors deter-Cancer Celmined the degree to which these overlap-
ped with those defined by methylome
profiling. Interestingly, almost 90% of G-
CIMP tumors (n = 21/24) were classified
into the proneural subgroup by mRNA
expression, suggesting that this pattern
of methylation contributes to the develop-
ment of proneural GBM. However, only
30% (n = 21/71) of all proneural GBM dis-
played the G-CIMP; thus G-CIMP prob-
ably contributes to the development of
just a subset of proneural GBMs.
The authors then turned their attention
to determining whether G-CIMP+ proneu-
ral GBM represents a distinct disease
subgroup. Notably, Euclidean statistics
provided further evidence that G-CIMP+
proneural GBMs are distinct from G-
CIMP tumors. In addition, patients with
G-CIMP+ proneural GBM were shown to
be significantly younger at the time of
diagnosis and had a significantly better
prognosis than patients diagnosed with
non-G-CIMP proneural tumors.
Although these findings certainly suggest
that G-CIMP+ and G-CIMPGBMs are
distinct pathological entities, subsequent
integrated genomic analyses performed
by the authors support this notion most
strongly. Using resequence data previ-
ously generated by the TCGA, the authors
identified nine genes containing somatic
mutations that were significantly associ-
ated with proneural G-CIMP+ GBM.
These included IDH1, DST, EIF2AK4,
EPHB4, FGFR4, LEMD3, MAPK7,
TNFRSF10A, and TRPM3. Remarkably,
IDH1 was mutated in 18 of 23 G-CIMP+
GBMs, whereas 184 G-CIMP tumors
contained the wild-type allele. Prior DNA
resequencing studies have shown IDH1
mutations are enriched in secondary
GBM cases and younger individuals and
associated with increased patient survival
(Yan et al., 2009). The positive associationl 17, May 18, 2010 ª2010 Elsevier Inc. 419
Figure 1. The Continued Efforts of the TCGA Project Are Advancing
Our Understanding of Glioblastoma
With genomic technologies, the TCGA has layered detailed patterns of tumor
gene expression, mutation and, in this issue of Cancer Cell, methylation over
knowledge of histology and clinical characteristics to provide a comprehensive
view of the disease.
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G-CIMP+ suggests that they
might cooperate in the trans-
formation of cells within the
glial lineage. Alternatively,
subtypes of normal neural
cells may exist that contain
a CIMP and are uniquely
susceptible to transformation
by mutations in IDH1. Func-
tional studies will be required
to clarify these associations.
An obvious question posed
by the discovery of the
G-CIMP is whether it impacts
global patterns of mRNA
expression in GBM. Answer-
ing this question is not
straightforward given that hy-
permethylation might have
regional as well as global
effects on gene expression
that are complicated further
by changes in DNA sequence
and copy number. As a first
step to determine the impactof the methylome on the transcriptome
in GBM, the authors identified 1550
unique genes that were differentially hy-
permethylated (1520) or hypomethylated
(30) between G-CIMP+ and G-CIMP pro-
neural GBMs tumors and looked to see
which of these also showed differential
expression. Two hundred and sixty-three
genes were downregulated and hyper-
methylated in G-CIMP+ compared to
G-CIMP proneural tumors. Interestingly,
these included FABP5, PDPN, CHI3L1,
and LGALS3: elevated expression of
these genes has been independently
associated with poor outcome in GBM.
Furthermore, the authors noted a 263
downregulated and hypermethylated
G-CIMP+ gene signature that has been
associated previously with lower grades
of glioma.
Finally, using MethyLight technology,
the authors distilled their extensive420 Cancer Cell 17, May 18, 2010 ª2010 ElsG-CIMP methylome signature into an
eight gene panel of seven hypermethy-
lated loci (ANKRD43,HFE,MAL, LGALS3,
FAS-1, FAS-2, andRHO-F) and one hypo-
methlyated locus (DOCK5). Using this
panel and an extensive separate collec-
tion of tumors, the authors validated the
frequency of the G-CIMP signature and
its association with mutant IDH1 in GBM
and confirmed that the G-CIMP occurs
with a much higher frequency in low-
grade gliomas. Interestingly, among the
lower-grade tumors, G-CIMP was twice
as common in oligodendrogliomas as
compared to astrocytomas and corre-
lated with improved patient outcome.
This work by Noushmehr and
colleagues represents an important step
along the road toward understanding the
biology of GBM. The correlation of G-
CIMP status with other molecular and
histological characteristics of the diseaseevier Inc.highlights the value of the
unbiased and systematic
approach to cancer geno-
mics promoted by the
TCGA. In particular, the
finding that all grades of
G-CIMP+ gliomas across
multiple tumor collections
display a favorable outcome
suggests that this methylome
promotes a less aggressive
tumor phenotype. These
data contribute to the ex-
panding legacy of TCGA that
should lead us beyond correl-
ative genomics to a real
understanding of the biology
and treatment of all types of
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